Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-027 - Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Presenter: Edward B. Garon- Abstract
Loading...
-
+
EP14.01 - Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
-
+
EP14.01-015 - IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
Presenter: Luis Paz-Ares- Abstract
Loading...
-
+
OA06 - Impact of COVID-19 on Cancer Management and Protection from Vaccines
- 11:00 - 12:10
- 8/08/2022
- Location: Lehar 1
- Not for CME Credit
- Type: Oral
- Track: Management of Lung Cancer in the Era of COVID-19
- Moderators:Marina Chiara Garassino, Christian Grohe
-
+
OA06.06 - Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis
11:32 - 11:42 | Presenter: Amit Kulkarni
- Abstract
Loading...
-
+
OA12 - Novel and Combination Strategies for SCLC
- 16:00 - 17:00
- 8/08/2022
- Location: Hall C8
- Not for CME Credit
- Type: Oral
- Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
- Moderators:Alessandra Curioni-Fontecedro, Kostas Syrigos
-
+
OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
16:32 - 16:42 | Presenter: Charles M Rudin
- Abstract
Loading...
-
+
IS24 - Industry Sponsored Symposium by MSD: New Frontiers in the Management of NSCLC
- 18:00 - 19:00
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Industry Symposium
- Track: N/A
-
+
Session Moderator
18:00 - 18:00 | Presenter: Solange Peters
- Abstract
Loading... -
+
IS24.01 - Welcome and Introduction
18:00 - 18:05 | Presenter: Solange Peters
- Abstract
Loading... -
+
IS24.02 - Evolving Treatment Landscape in Metastatic NSCLC
18:05 - 18:15 | Presenter: Solange Peters
- Abstract
Loading... -
+
IS24.06 - Closing Remarks
19:00 - 19:00 | Presenter: Solange Peters
- Abstract
Loading...
-
+
IBS17 - Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings? (Ticketed Session) (In-person Access Only)
- 07:30 - 08:15
- 8/09/2022
- Location: Lehar 3
- IASLC CME Accredited
- Type: Interactive Breakfast Session
- Track: Tumor Biology and Biomarkers
-
+
IBS17.02 - Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?
07:45 - 08:00 | Presenter: Solange Peters
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.04 - Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
14:42 - 14:52 | Presenter: Solange Peters
- Abstract
Loading...
